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Abstract
Background: Acute allograft rejection is a major cause of early mortality in the first year after heart transplantation
in adults. Although endomyocardial biopsy (EMB) is not a perfect “gold standard” for a correct diagnosis of acute
allograft rejection, it is considered the best available test and thus, is the current standard practice. Unfortunately,
EMB is an invasive and costly procedure that is not without risk. Recent evidence suggests that acute allograft
rejection causes delays in ventricular repolarization and thereby increases the cellular action potential duration
resulting in a longer QT interval on the electrocardiogram (ECG). No prospective study to date has investigated
whether such increases in the QT interval could provide early detection of acute allograft rejection. Therefore, in
the Novel Evaluation With Home Electrocardiogram And Remote Transmission (NEW HEART) study, we plan to
investigate the potential benefit of daily home QT interval monitoring to predict acute allograft rejection.
Methods/design: The NEW HEART study is a prospective, double-blind, multi-center descriptive research study. A
sample of 325 adult heart transplant recipients will be recruited within six weeks of transplant from three sites in
the United States. Subjects will receive the HeartView™ ECG recorder and its companion Internet Transmitter,
which will transmit the subject’s ECG to a Core Laboratory. Subjects will be instructed to record and transmit an
ECG recording daily for 6 months. An increase in the QTC interval from the previous day of at least 25 ms that
persists for 3 consecutive days will be considered abnormal. The number and grade of acute allograft rejection
episodes, as well as all-cause mortality, will be collected for one year following transplant surgery.
Discussion: This study will provide “real world” prospective data to determine the sensitivity and specificity of QTC
as an early non invasive marker of cellular rejection in transplant recipients during the first post-transplant year. A
non-invasive indicator of early allograft rejection in heart transplant recipients has the potential to limit the number
and severity of rejection episodes by reducing the time and cost of rejection surveillance and by shortening the
time to recognition of rejection.
Trial Registration: ClinicalTrials.gov: NCT01365806
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The prevalence of American adults living with a heart
transplant was 20,369 in 2009, the most recent year for
which complete data are available [1]. Acute allograft
rejection is a major cause of early mortality, a rate that
reaches 13% in the first year after heart transplantation
in adults [1,2]. According to the 2011 annual United
States data published from the International Society for
Heart Lung Transplantation Registry, 26% of heart
transplant recipients have at least one rejection episode
within the first year following transplant surgery [2].
Acute rejection remains the most common cause of
morbidity and rehospitalization. Jalowiec [3] reported
that 64% of heart transplant recipients were rehospita-
lized during the first year after transplant surgery (med-
ian length of stay, 16 days), and 37% were rehospitalized
more than once. Rejection is also a primary cause of
urgent re-transplantation, a situation that is perceived
by some to be morally unfair because these patients are
allowed a second transplant while others are waiting
and often dying before receiving their first transplant.
Thus, the financial, physical, and emotional toll asso-
ciated with acute rejection is significant.
In order to detect the early stages of rejection so that
more aggressive and early immunosuppressant therapy
can be initiated, frequent biopsies of heart tissue are per-
formed (typically, weekly or every other week in the first
three months and then monthly or every other month
during the first year). Although endomyocardial biopsy
(EMB) is not a perfect “gold standard” for a correct diag-
nosis of acute allograft rejection, it is considered the best
available test and thus, it is the current standard practice.
Unfortunately, EMB is an invasive and costly procedure
that is not without risk [4,5]. If a simple noninvasive bio-
marker could be identified to detect the early stages of
acute rejection, it might be possible to reduce the num-
ber of invasive biopsy procedures and to initiate earlier
therapy that might prevent death from severe rejection.
Alternatives to invasive EMB monitoring have been
the subject of recent study. Most prominently, the use
of a commercially available test, the AlloMap, that
determines gene-expression profiling of recipient leuko-
cytes, was tested against routine EMB to determine
whether adverse events (a composite of allograft dys-
function, death, or retransplantation) differed between
patients who received standard EMB monitoring and
those who received monitoring by gene-expression pro-
filing [6]. Although the authors concluded that the
gene-expression profiling was not inferior to EMB in its
association with adverse events, only 6 of 34 rejection
episodes in the AlloMap group were identified solely on
the basis of the profiling test [6]. Further, the wide con-
fidence intervals for adverse events translated into as
much as a 68% increase in risk with AlloMap monitor-
ing [7]. Most participants were randomized more than
one year after transplant, which limits the generalizabil-
ity of these findings to the higher risk, early (< one year)
post-transplant group that we propose to study.
Other investigators have focused on the electrocardio-
gram (ECG) as a potential marker of allograft rejection
because it is noninvasive and easily measured. Previous
studies have investigated the QT interval, an indirect mea-
sure of the cellular action potential duration of ventricular
myocytes. The QT interval, defined as the interval from
the beginning of the QRS complex to the end of the T
wave, reflects the time that elapses between the initial fast
depolarization of the ventricles and their subsequent repo-
larization. Recent evidence suggests that acute allograft
rejection causes delays in ventricular repolarization and
thereby increases the cellular action potential duration
resulting in a longer QT interval on the ECG [8-12]. Find-
ings from two studies suggest that the QT interval is
linked to acute allograft rejection and three other studies
have linked an increased QT interval with mortality (Table
1). However, these studies all have serious limitations. All
but one were retrospective analyses. All involved hospital
or clinic-acquired ECGs, typically done at baseline seven
days following transplant surgery and then annually or at
the time of hospitalization for acute severe allograft rejec-
tion. Thus, none of the studies could report whether QT
interval prolongation was an early sign of rejection or sim-
ply the result of severe, irreversible rejection. Another lim-
itation was that all but one study made no mention of
investigators being blinded from clinical information
about allograft rejection. Thus, it is possible that the
researchers making manual measurements of the QT
interval were biased by knowing whether the subject did
or did not have acute allograft rejection. Despite these lim-
itations, there is evidence that an increase in the QT inter-
val is linked to acute allograft rejection and mortality.
No prospective study to date has investigated whether
such increases in the QT interval could provide early
detection of acute allograft rejection. In addition,
advances in home ECG monitoring have evolved and
become less cumbersome and more patient-friendly.
Therefore, in the Novel Evaluation With Home Electro-
cardiogram And Remote Transmission (NEW HEART)
study, we plan to take advantage of novel ECG technol-
ogy to investigate the potential benefit of daily home
QT interval monitoring to predict acute allograft rejec-
tion following heart transplantation.
Methods/design
Design
The NEW HEART study is a prospective, double-blind,
multi-center descriptive research study. The primary
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Page 2 of 9aims of the NEW HEART study are to: 1) determine
whether an increase in the QT interval during the first
6 months following heart transplant is a sensitive and
specific biomarker for acute allograft rejection; 2) deter-
mine the timing of initial increased QT interval relative
to biopsy-diagnosed stages of mild, moderate, and severe
allograft rejection.
Secondary aims are to: 1) determine whether an
increase in the QT interval during the first 6 months
following heart transplant predicts mortality within the
first year, and 2) explore additional ECG measurements
that might predict acute allograft rejection or death.
Sample
A sample of 325 adult heart transplant recipients will be
recruited from the Columbia University-New York Pres-
byterian Medical Center (CU-NYP), the University of
California, Los Angeles (UCLA), and Cedars Sinai Medi-
cal Center (CSMC) in Los Angeles, CA. Respectively,
demographic characteristics at these sites are: male
(68.9%, 75.7%, and 79.7%); White (53.1%, 59.1%, 73.4%);
Black (20.3%, 9.4%,12.5%); Latino (14.5%, 19.9%, 9.4%)
and Asian (11.3%, 10.5%, 3.1%) [1]. Inclusion criteria
are: 1) ≥ 18 years of age, 2) first heart transplant surgery
within six weeks of their transplant surgery, 3) not
enrolled in other research studies that conflict with the
study design, 4) clinically stable at time of enrollment (i.
e. no clinical symptoms of allograft impairment with
ejection fraction ≥ 45%).
Instrumentation
QT interval was selected for monitoring in this study
because it is the ECG element most likely to reflect
early acute rejection, as previously noted, and because in
the setting of early post-transplantation, it is free of neu-
rologically mediated influences. In the first year after
transplantation, the cardiac allograft is denervated [13].
A potential major benefit of allograft denervation in the
NEW HEART study is that without the confounding
influences of heart rate and autonomic nervous system
activity, an observed increase in the QT interval is likely
to indicate abnormal ventricular repolarization due to
another cause, such as acute allograft rejection.
After a thorough search of the available technology,
the HeartView™ ECG Personal Recorder-Transmitter
(Aerotel Medical, Israel) was selected. The ECG device
records 10 s of the six limb leads (I, II, III, aVR, aVL,
aVF) and two precordial leads (V5 and V6 will be used
Table 1 Human Studies on QT Interval Prolongation after Heart Transplantation
#
Subjects
Author/Yr
Study Design Major Findings Study Limitations Implications for
NEW HEART Study
N=6 5
Richartz et
al. 1998
[8]
Prospective; Rejection
during in-hospital period
1. Mean QTC = 449 ± 2 ms without
rejection; 517 ± 11 ms with rejection (p <
0.001) 2. > 10% increase in QTC predicted
rejection with sensitivity, 86%; specificity,
88%
1. Only observed rejection during
hospitalization for transplant surgery 2.
Analyzed only 3 ECGs per subject 3. ECG
analyzers not blinded from clinical
information about rejection
An increase in the QT
interval predicts
acute allograft
rejection
N=5 2
Kolasa et
al. 2005
[9]
Retrospective; Long-term
mortality over 7 yrs
Poorer survival over 7 yrs in subjects who
had a > 10 ms per year change in their
QTC interval on their annual ECG
1. Link to rejection not studied 2.
Analyzed only one ECG per year
As little as a 10 ms
change in the QT
interval is linked to
mortality
N = 200
Tenderich
et al. 2006
[10]
Retrospective; Rejection
during first 3 months
> 25 ms increase in QTC interval predicted
acute allograft rejection with sensitivity,
77%; specificity, 96%.
1. Only analyzed 2 ECGs per subject 2.
ECG analyzers not blinded from clinical
information about rejection
Increase in QT
interval predicts
acute rejection
during the period of
interest
N = 587
Vrtovec et
al. 2006
[11]
Retrospective; Long-term
mortality up to 17 yrs
1. Patients with ≥ 10% increase in QTC
interval between 1
st and 2
nd year post-
transplant had 6.86 times higher risk of
dying.2. ≥ 10% increase in QTC was the
only independent predictor of long- term
mortality on multivariate analysis 3. Trend
was a decreasing QTC over the yrs
suggesting sympathetic reinnervation
1. Link to rejection not studied 2.
Analyzed only one ECG per year
An increase in the QT
interval is linked to
mortality
N=7 1
Vrtovec et
al. 2008
[12]
Retrospective; 1- year all-
cause & SCD mortality in
subjects with severe
acute rejection
1. QTC was longer in SCD group than in
survivors (475 ± 57 versus 437 ± 36 ms; p
= 0.02) 2. Patients who had > 10%
increase in QT interval during a severe
acute rejection episode were at increased
risk for SCD.
1. Limited to just patients with severe
rejection; unable to tell whether
increased QT interval could predict
earlier, milder forms of rejection 2.
Analyzed just 2 ECGs per subject (one at
baseline 7 days after surgery, second at
time of rejection)
An increase in the QT
interval is linked to
mortality
ms = millisecond; SCD = sudden cardiac death; QTc = QT interval corrected for heart rate
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a sampling rate of 500 samples per second which is the
standard resolution recommended for diagnostic electro-
cardiography. The device’s reliability and validity for
ECG diagnosis are evidenced by approval by the U.S.
Food & Drug Administration that requires the device to
meet criteria stipulated by the Association for the
Advancement of Medical Instrumentation for electrocar-
diograph instruments [14].
The HeartView™ will be used to transmit the sub-
ject’s ECG to the Core Laboratory at UCSF ("Drew
Lab”) (Figure 1). Subjects will be given HeartView™ and
Internet Transmitter devices (Aerotel Medical, Israel)
for the 6-month monitoring period. Once the patient
records his ECG, the HeartView™ device will automati-
cally seek, find, and upload the ECG by wireless Blue-
tooth communication to the Internet Transmitter. Then,
using mobile phone technology (subscriber identity
module [SIM] card), the Internet Transmitter device
will automatically seek, find, and send the digital ECG
to a UCSF server via wireless General Packet Radio Ser-
vices (GPRS) internet access. Thus, subjects do not have
to dial a telephone to transmit the ECG, nor do they
need to have a home computer or even be computer lit-
erate. Subjects need only to record their ECG; the rest
will be automatic.
Procedures
Participants will be recruited either while they are in the
hospital for transplant surgery, or if that is inconvenient,
during their first clinic visit following transplant surgery.
After informed consent is obtained, demographic and
clinical data will be collected by self-report and by med-
ical record audit. At the time of each EMB, data from
the medical record will be abstracted to confirm current
medications, serum levels of anti-rejection medications,
clinical data regarding EMB results, and other clinical
data reflecting myocardial performance consistent with
rejection status. Only one anti-rejection medication
(tacrolimus) is associated with an increased QT interval.
If a patient is on chronic tacrolimus therapy without a
change in dosage, it should not interfere with the daily
ECG monitoring measurement because we will be com-
paring each patient with him/herself and noting any
change from the previous day’sQ Ti n t e r v a l .H o w e v e r ,
we will track initiation or change in any QT-prolonging
drug. On their website, the Arizona Center for Educa-
tion and Research on Therapeutics [15] maintains a
comprehensive list of QT- prolonging drugs that we
have incorporated into the medications section of our
electronic database system. Further, on a quarterly basis,
we will continue to reference this website for new drugs
as they come to market and update our data capture to
include those associated with QT-prolongation.
The other drug class that patients may be taking is 3-
Hydroxy-3-Methyl-Glutaryl Coenzyme A Reductase
inhibitors (i.e., statins) which are known to shorten the
QT interval. Thus, we will also monitor statin therapy.
To insure patient safety, we will notify patients’ trans-
plant cardiologists within 48 h of the detection of any
QTc interval exceeding the population 99th percentile
for adult males (> 470 ms) or females (> 480 ms) [16].
At the time of informed consent and enrollment, sub-
jects will receive the HeartView™ recorder and its
Figure 1 HeartView™ Device and Transmission System.
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subject’s ECG as described earlier. Subjects will be asked
to record a 10-s 8-lead ECG daily for 6 months.
Participants and their caregivers, if available, will be
instructed in the use of the HeartView device using a
standardized training booklet. Each enrollee will be
given the opportunity to practice transmission and will
receive feedback, if needed, prior to the beginning of
daily recordings. Daily recordings will be monitored by
study personnel to insure quality of transmissions.
Participants will be instructed to make and upload
ECG recordings at any time of day that is convenient
for them, although they will be urged to select a consis-
tent time to promote adherence to recording. Across
participants, a standard recording time is not required
because in the early post transplant period complete
allograft denervation results in failure of parasympa-
thetic or sympathetic nerves to influence heart rate. In
normal individuals at rest, parasympathetic influences
via the vagus nerve predominate resulting in a resting
heart rate of 60-90 beats/min in adults. However, with-
out such parasympathetic influence on the allograft,
transplant recipients experience a permanent tachycar-
dia (99 ± 12 beats/min) and exhibit little heart rate
variability over a 24 h period [17]. For the current
study, this means that subjects will be able to record
their daily ECGs at any timew i t h o u tt h ec o n f o u n d i n g
influence of 24-h variability on ECG intervals. However,
participants will be instructed to wait for at least ten
minutes after exercising before recording an ECG. This
is necessary because allograft beta receptors are func-
tional early after transplant [17] and respond to
increases in circulating catecholamines, such as that eli-
cited by exercise. This post-transplant response to exer-
cise is less immediate than in normal individuals and
after cessation of exercise, peak heart rate also recedes
at a slower pace, over about a 10-min period [17].
Analysis of ECG monitoring data
The ECG will be sent to a large server hosted by the
UCSF Office of Academic and Administrative Informa-
tion Systems (OAAIS). The server is a secure, highly
redundant data center with 24/7 availability due to
back-up generators that protect against power outages.
The system provides nightly data backup. Investigators
in the Drew Lab will access the ECG data by logging on
with a username and password via a Virtual Private Net-
work (VPN), which encapsulates data transfers between
networked devices not on the same private network and
keeps the transferred data private from other devices.
Investigators who analyze the daily ECG data will be
blinded from all information regarding the subject’s clin-
ical status and biopsy results. In addition, pathologists
who grade the biopsies and clinicians who provide
medical care in the transplant clinics will be blinded
from the QT interval monitoring data.
QT and RR intervals will be made in a computer-
assisted manner. The Aerotel measurement software
provides a zooming feature to enlarge ECG waveforms
for better visualization. In addition, electronic calipers
are provided so that the researcher will select the appro-
priate waveform onset and offset points and the compu-
ter software will provide the interval value in
milliseconds (ms). The QT interval will be measured
from the onset of the QRS waveform to the end of the
T waveThe end of the T wave will be defined as the
intersection of a tangent to the steepest slope of the last
limb of the T wave and the baseline (Figure 2) [18]. A
standardized correction to account for the effect of HR
will be applied (QTC). An increase in the QTC interval
from the previous day of at least 25 ms that persists for
3 consecutive days will be considered abnormal [10].
To explore the potential diagnostic and prognostic
value of additional ECG measurements, the following
variables will also be measured on the daily ECG
recordings: cardiac rhythm, heart rate, P wave and QRS
duration, PR interval, QRS amplitude, and the interval
from the peak of the T wave to the end of the T wave
[19]. A prolonged TPEAK -T END interval is thought to
represent heterogeneity of ventricular repolarization
across the 3 layers of the myocardial wall [20] and has
been associated with risk for sudden cardiac death from
torsades de pointes [21].
Diagnosis of acute allograft rejection
Rates of acute allograft rejection have varied, but the
most recent rates of rejection in the first 6 months after
transplant are reported to be 25 to 35% [2]. The diagno-
sis of acute allograft rejection is made by an EMB which
will be performed in the hospital cardiac catheterization
laboratory at each site. Generally, 3-6 biopsy specimens
of the right ventricular endocardium are taken to mini-
mize false negative tests. Each site will follow its own
acute rejection surveillance protocol. In general, these
protocols require weekly or biweekly EMBs during the
first two to three post-transplant months. After that
time, biopsies are performed less frequently, based on
clinical judgment and risk of rejection. At each site,
EMBs will be graded by clinical pathologists experienced
with the heart transplant population and using the
International Society of Heart and Lung Transplantation
standards for acute rejection. Although early reports
indicated inter-operator variability in the interpretation
of EMB results [22], the use of the standardized grading
system has improved the reliability and validity of the
measurement. Current variability in interpretation of
biopsy results occurs mainly in the diagnosis of Grade 2
rejection by local pathologists which may be
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called Quilty lesions [23,24]. To control for potential
variability, we will monitor and record clinical and
hemodynamic indicators of myocardial performance,
which are obtained at the time of each biopsy or at reg-
ular clinical assessments, to support the biopsy interpre-
tation, particularly regarding Grade 2 rejection. Such a
multi-factorial approach to identification of rejection has
been recommended [24].
Follow-up and end-points
The number and grade of acute allograft rejection epi-
sodes will be collected for a period of one year following
transplant surgery. Data on all-cause mortality within
the first year will be collected. Because all transplant
centers are required to report their data to the trans-
plant registry, we anticipate no loss to follow-up or
missing data regarding rejection or death.
Data management
To insure accuracy of data collection, all sites will use a
secure web-based data capture site, Research Electronic
Data Capture (REDCap) [25], which is sponsored by a
consortium of 118 research institutions. REDCap offers
a stream-lined process for rapidly building a database,
an interface for data collection and validation, and auto-
mated export procedures for download to statistical
packages. As part of our pilot study, we developed,
initiated, and refined a REDCap database which is ready
for use in the proposed study.
Statistical analysis
Using the variable definitions in Table 2, a logistic
regression analysis will be performed with the indepen-
dent variable being presence/absence of the ECG criteria
(ΔQTC ≥ +25 ms × 3 days [10]) and the dependent
variable being presence/absence of acute allograft rejec-
tion. Odds ratios and confidence intervals will be
reported as well as the universal proportions used to
determine the value of new diagnostic criteria (sensitiv-
ity, specificity, positive/negative predictive value, and
predictive accuracy, Table 3).
Descriptive statistics ( m e a n s±S D )w i l lb eu s e dt o
describe the average time period between the develop-
ment of the ECG criterion and biopsy evidence of rejec-
tion. In addition, we will report the proportion of
subjects who develop the ECG criterion (≥ +25 ms
increase in QT interval from previous day lasting 3 con-
secutive days [10]) before, during, or after the stages of
mild, moderate, and severe rejection.
The Kaplan-Meier method with the log-rank test will
be used to estimate survival curves over one year and to
compare all-cause mortality in patients who are positive
or negative for the QTC criterion. Cox Proportional
Hazard modeling will be used to control for baseline
differences between groups and for tacrolimus use.
Logistic regression will be used with the dependent
variables of rejection (yes/no) and all- cause mortality
(yes/no). In both regressions, tacrolimus dosage (with
“0” entered if the patient is not receiving tacrolimus)
will be included as a covariate in the model. If any of
the explorative variables are statistically significant, a
multiple logistic regression model will be used including
the ECG criterion of interest to determine whether addi-
tional ECG criteria are independent predictors of rejec-
tion and death.
Ethics approval
Institutional Review Board (IRB) approvals have been
obtained at all participating sites. Although this is not a
randomized clinical trial, we are implementing an exter-
nal Data Safety Monitoring Board (DSMB), consisting of
Figure 2 Measurement of QT Interval. A tangent is drawn to the steepest slope of the last limb of the T wave; the end of the T wave is the
intersection of this tangent with the baseline.
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DSMB will be charged with providing guidance regard-
ing subject recruitment and retention, issues related to
implementation of the study protocol, any adverse
events, and any complaints or problems emanating from
participants. The DSMB will meet at least annually to
review study progress and make recommendations to
the investigators.
Discussion
An increased QTC interval in heart transplant recipients
is linked to acute allograft rejection and death. Normal
v a r i a t i o ni nQ T C intervals over 24 h due to changing
autonomic nervous system tone does not occur in heart
transplant recipients because transplant surgery causes
denervation of the allograft. Thus, an increase in QTC is
likely to indicate cellular dysfunction that occurs with
acute rejection. Prior research is inadequate to deter-
mine whether monitoring the QT interval would be
valuable to detect acute allograft rejection because the
studies have been retrospective and involved just a few
ECGs recorded periodically and analyzed by investiga-
tors who were not blinded from information about
rejection episodes.
The NEW HEART study focuses on the potential for
f u t u r er e d u c t i o ni nt h en u m b e ro fE M B sw h i c ht r a n s -
plant recipients must endure in the first year following
transplantation. While EMB remains the gold standard
for detection of cellular rejection in heart transplant
recipients, it is costly, inconvenient, and not without
risk [4,5,26]. Increased QTC has been linked to acute
allograft rejection, but has not been systematically evalu-
ated in prospective studies. This investigation will pro-
vide “real world” prospective data to determine the
Table 2 Variable definitions for statistical analysis
Variable Definition Type of Variable
ΔQTC ≥ +25 ms increase in QTC interval from previous day lasting 3 consecutive days [10] Continuous (expected range, 10-100
ms)
Acute allograft
rejection
EMB category 1R or 2R or 3R with confirmation by
treating physician
Categorical; dichotomous (yes/no) No
=0 ;Y e s=1 Ro r2 Ro r3 R
Days to
rejection
Number of days from first positive ECG criterion to mild, moderate, or severe rejection
diagnosis. If the ECG criterion follows rejection, a negative # of days
will be reported.
Continuous (expected range -365 to
+365)
Acute
rejection
severity
EMB category: 1R (mild), 2R (moderate), 3R (severe) Categorical
Cardiac
rhythm
Sinus rhythm, atrial fibrillation, atrial flutter, junctional rhythm Categorical
Heart rate Heart rate per minute calculated from 30 s rhythm strip Continuous (expected range, 60-120)
P wave
duration
Interval from beginning to end of P wave in ms (measure of intra-atrial conduction delay) Continuous (expected range, 70-126
ms)
QRS duration Interval from beginning to end of the QRS waveform Continuous (expected range, 72-160
ms)
PR interval Interval from the beginning of the P wave to the beginning of the QRS complex measured
in ms. PR interval > 200 ms indicates an abnormal delay of conduction (1
st degree AV
block).
Continuous (expected range, 112-240
ms)
QRS
amplitude
Height of QRS waveform in μV Continuous (expected range, 500-1000
μV
TPEAK -T END Interval from the peak of the T wave (or nadir in inverted T waves) to the end of the T
wave in ms. Prolonged TPEAK -TEND indicates heterogeneity of repolarization and risk for
arrhythmia
Continuous (expected range, 112-240
ms)
Table 3 Definitions of Universal Proportions
Criterion Definition
Sensitivity Proportion of those with acute rejection who are positive for the ECG criterion
Specificity Proportion of those without rejection who are negative for the ECG criterion
Positive Predictive Value Proportion of patients with positive ECG criterion who have rejection
Negative Predictive Value Proportion of patients with negative ECG criterion who do not have rejection
Predictive Accuracy #true positives ± true negatives by the ECG criterion
Total # of patients enrolled in the study × 100
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sive marker of cellular rejection in transplant recipients
during the first post-transplant year.
A non-invasive indicator of early allograft rejection in
heart transplant recipients has the potential to limit the
number and severity of rejection episodes by reducing
the time and cost of rejection surveillance and by short-
ening the time to recognition of rejection. Additionally,
achievement of the aims of the current study may iden-
tify other ECG parameters relevant for non-invasive
allograft rejection monitoring and may provide support
for a randomized controlled trial to determine the effi-
cacy and cost-effectiveness of this type of noninvasive
ECG monitoring compared with standard EMB
surveillance.
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